Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 6/20 | 0.62 |
| ▸ | CTSK | P43235 | 5/20 | 0.62 |
| ▸ | REN | P00797 | 3/20 | 0.54 |
| ▸ | CTSD | P07339 | 1/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.50 |
| ▸ | CTSB | P07858 | 1/20 | 0.50 |
| ▸ | CASP1 | P29466 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15462710 | 1.00 | CTSS (0.62) | CTSSCTSKRENCTSDCTSL | |
| SCHEMBL3469003 | 0.93 | CTSS (0.69) | CTSSCTSKRENCTSLCTSB | |
| SCHEMBL4024913 | 0.93 | CTSS (0.69) | CTSSCTSKRENCTSLCTSB | |
| SCHEMBL3469005 | 0.93 | CTSS (0.69) | CTSSCTSKRENCTSLCTSB | |
| SCHEMBL4024908 | 0.93 | CTSS (0.69) | CTSSCTSKRENCTSLCTSB | |
| SCHEMBL23771865 | 0.91 | CTSS (0.67) | CTSSCTSKRENCTSDCTSL | |
| SCHEMBL11369521 | 0.88 | CTSS (0.63) | CTSSCTSKRENCTSLCTSB | |
| SCHEMBL29275096 | 0.87 | CTSS (0.60) | CTSSCTSKKMT2AMEN1ATM | |
| SCHEMBL8614308 | 0.87 | CTSS (0.60) | CTSSCTSKKMT2AMEN1ATM | |
| SCHEMBL17269324 | 0.87 | CTSS (0.60) | CTSSCTSKKMT2AMEN1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10975119-B2 | Selective cysteine protease inhibitors and uses thereof | GENESIS TECHNOLOGIES LIMITED (BB) | 2021-04-13 | — | — | US | disclosed |
| US-20180186833-A1 | SELECTIVE CYSTEINE PROTEASE INHIBITORS AND USES THEREOF | GENESIS TECH LIMITED (BB) | 2018-07-05 | — | — | US | disclosed |
| US-9944674-B2 | Selective cysteine protease inhibitors and uses thereof | GENESIS TECHNOLOGIES LIMITED (BB) | 2018-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180186833-A1 | SELECTIVE CYSTEINE PROTEASE INHIBITORS AND USES THEREOF | SERPINB1, SERPINE1, CASP5 | CTSS 48/4885CTSK 138/4885REN 2062/4885 |
| US-10975119-B2 | Selective cysteine protease inhibitors and uses thereof | SERPINB1, SERPINE1, CASP5 | CTSS 48/4885CTSK 128/4885REN 2289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.